Rochester, NY – Bio-Optronics Inc., a leading software and services solutions provider to the healthcare and life sciences industry announced they are teaming up with OmniComm Systems, Inc. (OmniComm), a global leading provider of clinical data management technology. Under the agreement, the two companies will integrate OmniComm TrialMaster EDC with Bio-Optronics Clinical Conductor clinical trial management system (CTMS) for multiple facilities at a major institution seeking to develop cures and treatments for cancer and other catastrophic diseases.
This multi-center children cancer research organization is looking to increase productivity and efficiency while reducing costs. This requires the integration of CTMS and electronic data capture (EDC) systems. Integrating these systems ensures that overlapping data is reported correctly in both systems, saving time and reducing the opportunity for errors. For most organizations, redundant data entry is a major source of operational inefficiency and errors.
EDC is typically the primary data source to recognize fundamental clinical metrics such as patient accrual, open query counts, and even reports adverse experiences. CTMS serves as the operational hub for a clinical trial, tracking and reporting on numerous components of a study, including study progress, completed visits, enrollment, financial activity, and regulatory compliance. The integration between EDC and CTMS allow individuals responsible for clinical operations to more proactively manage activities such as site initiation, patient recruitment, patient safety, site payments, capacity planning, and risk based monitoring.
“Bio-Optronics’ Clinical Conductor has proven to be an excellent complement to TrialMaster because of its dual focus on sponsor and site clinical trial management,” states Ken Light, EVP of Operations, OmniComm Systems. “Bio-Optronics has incorporated attention to details that allow sponsors and sites to configure, drill down, and report on the key operational criteria that document clinical activities, drive uniform processes, and support operational change. The BioOptronics team has been very impressive to work with, and the technology is fully compatible with OmniComm’s Microsoft-based technology stack.”
Integrating OmniComm TrialMaster EDC and Bio-Optronics’ Clinical Conductor enables data to synchronize in real time upon data entry. This constant communication ensures all parties are operating with the most current information.
“This co-venture exemplifies the impact of integrating best-in-class research applications from organizations with specific areas of expertise,” says Steve Bailey, VP of Clinical Conductor CTMS at Bio-Optronics. “OmniComm’s TrialMaster© EDC delivers the robust tools and insights that pair with Clinical Conductor to deliver the most complete end-to-end research management solution in the marketplace, and we look forward to building the relationship between our two companies and delivering value to the marketplace.”
About Bio-Optronics Inc.
Bio-Optronics, the creator of Clinical Conductor CTMS, is a leading software and services company that creates user-focused software and services for healthcare organizations that positively impacts the lives of patients around the world. Clinical Conductor CTMS is an established clinical trial management system, utilized by thousands of research organizations worldwide, designed to simplify and standardize complex research processes for businesses managing and conducting clinical trials. For more information, visit www.bio-optronics.com.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from over 4,800 clinical trials. For more information, visit www.omnicomm.com.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.